Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrenc

[News]

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

More... (http://www.news-medical.net/news/20101209/Clarient-introduces-Mammostrat-test-to-quantify-likelihood-of-breast-cancer-recurrence.aspx)